New paradigm on the treatment of patients
with EGFRm+ NSCLC
•
EGFRm, a chronic disease with a number of available options
•
EGFRTKIs, RR > 60%, PFS >10 mo, no relevant toxicity in 1st line and
2nd line (T790M+ pts)
•
Clear need for EGFR determinations in diagnostic and re-biopsy tumor
tissue
•
EGFR molecular determinations in blood should be implemented
